Arrowhead Pharmaceuticals, Inc.
LSE: 0HI3.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher R. Anzalone
- Employees
- 609
- Headquarters
- Pasadena, United States
- IPO year
- 2018
- Market cap
- $10.0B
- Website
- https://arrowheadpharma.com
Loading 0HI3…
Loading profile data…Frequently asked questions about 0HI3
What does Arrowhead Pharmaceuticals, Inc. (0HI3.L) do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
Where does 0HI3.L trade?
Arrowhead Pharmaceuticals, Inc. (0HI3.L) trades on the London Stock Exchange.
What sector is 0HI3.L in?
Arrowhead Pharmaceuticals, Inc. (0HI3.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Arrowhead Pharmaceuticals, Inc.?
Christopher R. Anzalone is the chief executive officer of Arrowhead Pharmaceuticals, Inc. (0HI3.L).
Where is Arrowhead Pharmaceuticals, Inc. headquartered?
Arrowhead Pharmaceuticals, Inc. is headquartered in United States.
Does 0HI3.L pay a dividend?
Arrowhead Pharmaceuticals, Inc. (0HI3.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HI3.L go public?
Arrowhead Pharmaceuticals, Inc. (0HI3.L) completed its initial public offering in 2018.